Literature DB >> 17138841

Pioglitazone inhibits androgen production in NCI-H295R cells by regulating gene expression of CYP17 and HSD3B2.

Petra Kempná1, Gaby Hofer, Primus E Mullis, Christa E Flück.   

Abstract

Thiazolidinediones (TZDs) such as pioglitazone and rosiglitazone are widely used as insulin sensitizers in the treatment of type 2 diabetes. In diabetic women with polycystic ovary syndrome, treatment with pioglitazone or rosiglitazone improves insulin resistance and hyperandrogenism, but the mechanism by which TZDs down-regulate androgen production is unknown. Androgens are synthesized in the human gonads as well as the adrenals. We studied the regulation of androgen production by analyzing the effect of pioglitazone and rosiglitazone on steroidogenesis in human adrenal NCI-H295R cells, an established in vitro model of steroidogenesis of the human adrenal cortex. Both TZDs changed the steroid profile of the NCI-H295R cells and inhibited the activities of P450c17 and 3betaHSDII, key enzymes of androgen biosynthesis. Pioglitazone but not rosiglitazone inhibited the expression of the CYP17 and HSD3B2 genes. Likewise, pioglitazone repressed basal and 8-bromo-cAMP-stimulated activities of CYP17 and HSD3B2 promoter reporters in NCI-H295R cells. However, pioglitazone did not change the activity of a cAMP-responsive luciferase reporter, indicating that it does not influence cAMP/protein kinase A/cAMP response element-binding protein pathway signaling. Although peroxisome proliferator-activated receptor gamma (PPARgamma) is the nuclear receptor for TZDs, suppression of PPARgamma by small interfering RNA technique did not alter the inhibitory effect of pioglitazone on CYP17 and HSD3B2 expression, suggesting that the action of pioglitazone is independent of PPARgamma. On the other hand, treatment of NCI-H295R cells with mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) inhibitor 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one (PD98059) enhanced promoter activity and expression of CYP17. This effect was reversed by pioglitazone treatment, indicating that the MEK/ERK signaling pathway plays a role in regulating androgen biosynthesis by pioglitazone.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17138841     DOI: 10.1124/mol.106.028902

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  19 in total

1.  Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial.

Authors:  Vanita R Aroda; Theodore P Ciaraldi; Paivi Burke; Sunder Mudaliar; Paul Clopton; Susan Phillips; R Jeffrey Chang; Robert R Henry
Journal:  J Clin Endocrinol Metab       Date:  2008-11-04       Impact factor: 5.958

2.  Effect of chronic treatment with Rosiglitazone on Leydig cell steroidogenesis in rats: in vivo and ex vivo studies.

Authors:  Janaína A Couto; Karina L A Saraiva; Cleiton D Barros; Daniel P Udrisar; Christina A Peixoto; Juliany S B César Vieira; Maria C Lima; Suely L Galdino; Ivan R Pitta; Maria I Wanderley
Journal:  Reprod Biol Endocrinol       Date:  2010-02-09       Impact factor: 5.211

3.  PPARγ agonist-induced alterations in Δ6-desaturase and stearoyl-CoA desaturase 1: Role of MEK/ERK1/2 pathway.

Authors:  Negar Saliani; Masoud Darabi; Bahman Yousefi; Behzad Baradaran; Mahmoud Shekari Khaniani; Maryam Darabi; Maghsod Shaaker; Amir Mehdizadeh; Tahereh Naji; Mehrdad Hashemi
Journal:  World J Hepatol       Date:  2013-04-27

4.  Multiple Signaling Pathways Coordinate CYP17 Gene Expression in the Human Adrenal Cortex.

Authors:  Marion B Sewer; Donghui Li; Eric B Dammer; Srinath Jagarlapudi; Natasha Lucki
Journal:  Acta Chim Slov       Date:  2008-01-01       Impact factor: 1.735

Review 5.  Fetal programming of adrenal androgen excess: lessons from a nonhuman primate model of polycystic ovary syndrome.

Authors:  David H Abbott; Rao Zhou; Ian M Bird; Daniel A Dumesic; Alan J Conley
Journal:  Endocr Dev       Date:  2008

Review 6.  Insulin and hyperandrogenism in women with polycystic ovary syndrome.

Authors:  Catherine G Baptiste; Marie-Claude Battista; Andréanne Trottier; Jean-Patrice Baillargeon
Journal:  J Steroid Biochem Mol Biol       Date:  2009-12-28       Impact factor: 4.292

7.  Risk management in the treatment of type 2 diabetes with pioglitazone.

Authors:  Giuseppe Derosa; Sibilla At Salvadeo
Journal:  Diabetes Metab Syndr Obes       Date:  2009-07-01       Impact factor: 3.168

8.  Weight reduction and pioglitazone ameliorate polycystic ovary syndrome after removal of a Sertoli-stromal cell tumor.

Authors:  Tsuyoshi Baba; Toshiaki Endo; Keiko Ikeda; Ayumi Shimizu; Miyuki Morishita; Yoshika Kuno; Hiroyuki Honnma; Tamotsu Kiya; Shin-Ichi Ishioka; Tsuyoshi Saito
Journal:  Int J Womens Health       Date:  2012-11-23

Review 9.  Are the adverse effects of glitazones linked to induced testosterone deficiency?

Authors:  M Carruthers; T R Trinick; E Jankowska; A M Traish
Journal:  Cardiovasc Diabetol       Date:  2008-10-15       Impact factor: 9.951

10.  Activation of PPARγ by Rosiglitazone does not negatively impact male sex steroid hormones in diabetic rats.

Authors:  Mahmoud Mansour; Elaine Coleman; John Dennis; Benson Akingbemi; Dean Schwartz; Tim Braden; Robert Judd; Eric Plaisance; Laura Ken Stewart; Edward Morrison
Journal:  PPAR Res       Date:  2009-06-11       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.